药捷安康-B(02617)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02617 药捷安康-B

未开盘 08-11 16:08:11

10.790

+0.040

+0.37%

最高11.180	最低10.700	成交量944.74万
今开10.790	昨收10.750	日振幅4.47%
总市值43.92亿	流通市值33.66亿	总股本4.07亿
成交额1.03亿	换手率3.03%	流通股本3.12亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02617","market":"HK","secType":"STK","nameCN":"药捷安康-B","latestPrice":10.79,"timestamp":1786435691697,"preClose":10.75,"halted":0,"volume":9447426,"delay":0,"changeRate":0.0037209302325580604,"floatShares":312000000,"shares":407000000,"eps":-0.8839522602616112,"marketStatus":"未开盘","change":0.04,"latestTime":"08-11 16:08:11","open":10.79,"high":11.18,"low":10.7,"amount":103033871,"amplitude":0.044651,"askPrice":10.8,"askSize":3500,"bidPrice":10.79,"bidSize":11500,"shortable":3,"etf":0,"ttmEps":-0.8834335198562471,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1786498200000},"marketStatusCode":0,"adr":0,"listingDate":1750608000000,"exchange":"SEHK","adjPreClose":10.75,"openAndCloseTimeList":[[1786411800000,1786420800000],[1786424400000,1786435200000]],"volumeRatio":0.315018,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02617","defaultTab":"news","newsList":[{"id":"1123933397","title":"药捷安康-B：CS Capital Co., Ltd.（国投招商投资管理有限公司）减持，好仓比例降至5.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=1123933397","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123933397?lang=zh_cn&edition=full","pubTime":"2026-08-10 17:15","pubTimestamp":1786353342,"startTime":"0","endTime":"0","summary":"CS Capital Co., Ltd.（国投招商投资管理有限公司）于2026年8月7日以每股均价13.74港元卖出药捷安康-B（02617）股份177.30万股，涉资约2436.10万港元。CS Capital Co., Ltd.（国投招商投资管理有限公司）此次减持前持有药捷安康-B好仓2006.33万股，占比6.42%；减持后持股量为1829.03万股，好仓比例降至5.85%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143271311","title":"药捷安康-B：先进制造产业投资基金二期减持，好仓比例降至5.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=1143271311","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1143271311?lang=zh_cn&edition=full","pubTime":"2026-08-10 17:11","pubTimestamp":1786353064,"startTime":"0","endTime":"0","summary":"Future Industry Investment Fund II (Limited Partnership) (先进制造产业投资基金二期 (有限合伙))于2026年8月7日以每股均价13.74港元卖出药捷安康-B 177.30万股H股，涉资约2436.10万港元。该基金此次减持前持有药捷安康-B好仓2006.33万股，占比6.42%；减持后持股量为1829.03万股，好仓比例降至5.85%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657660505","title":"药捷安康-B早盘涨超12% 核心产品替恩戈替尼片获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2657660505","media":"新浪港股","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657660505?lang=zh_cn&edition=full","pubTime":"2026-08-07 09:45","pubTimestamp":1786067100,"startTime":"0","endTime":"0","summary":"模拟交易客户端药捷安康-B早盘高开逾28%，截至发稿，涨幅收窄，股价上涨12.06%，现报12.92港元，成交额2.26亿港元。药捷安康昨晚发布公告称，公司自主研发的1类新药捷恩泰获国家药监局附条件批准上市，用于既往接受过系统性治疗和FGFR抑制剂治疗、且具有FGFR2融合或重排的晚期、转移性或不可手术切除的胆管癌成人患者。该疗法此前已获NMPA纳入优先审评及突破性治疗品种。据悉，该药物是药捷安康旗下首款获批上市的创新药。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-08-07/doc-inimmyem4200035.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02617","BK1161","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126093882","title":"异动解读｜药捷安康-B盘中上涨21.51%，核心产品捷恩泰获NMPA附条件批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1126093882","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1126093882?lang=zh_cn&edition=full","pubTime":"2026-08-07 09:30","pubTimestamp":1786066241,"startTime":"0","endTime":"0","summary":"8月7日，药捷安康-B盘中上涨21.51%，报14.04港元，成交额2036.61万港元。消息面上，公司8月6日公告，自主研发的1类新药捷恩泰获国家药品监督管理局附条件批准上市，用于既往接受过系统性治疗和FGFR抑制剂治疗、且携带FGFR2融合或重排的晚期、转移性或不可手术切除的胆管癌成人患者治疗。此外，替恩戈替尼全球注册性III期临床试验已于7月完成入组，商业化前景进一步明朗。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"药捷安康-B盘中上涨21.51%，核心产品捷恩泰获NMPA附条件批准上市","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657667795","title":"港股异动 | 药捷安康-B(02617.HK)高开近15% 核心产品替恩戈替尼片获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2657667795","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657667795?lang=zh_cn&edition=full","pubTime":"2026-08-07 09:24","pubTimestamp":1786065853,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657363981","title":"药捷安康-B(02617)：捷恩泰®(替恩戈替尼片)获国家药品监督管理局批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2657363981","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657363981?lang=zh_cn&edition=full","pubTime":"2026-08-06 20:06","pubTimestamp":1786018007,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药捷安康-B 发布公告，公司自主研发的1类新药捷恩泰获得国家药品监督管理局附条件批准上市，用于既往接受过系统性治疗和FGFR抑制剂治疗，且具有成纤维细胞生长因子受体2融合或重排的晚期、转移性或不可手术切除的胆管癌成人患者的治疗。此前，该疗法获NMPA纳入优先审评及突破性治疗品种。本次捷恩泰获得NMPA附条件批准上市，基于一项在中国开展的多中心、开放性、单臂、II期关键性临床试验。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1476951.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194785171","title":"药捷安康-B（02617）自主创新药捷恩泰获NMPA附条件上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1194785171","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194785171?lang=zh_cn&edition=full","pubTime":"2026-08-06 20:06","pubTimestamp":1786017963,"startTime":"0","endTime":"0","summary":"2026年8月6日，药捷安康-B公告称，公司自主研发的1类新药捷恩泰已获国家药品监督管理局附条件批准上市，用于治疗既往接受过系统性治疗和FGFR抑制剂治疗、且携带FGFR2融合或重排的晚期、转移性或不可手术切除的胆管癌成人患者。此前，该产品被NMPA纳入优先审评及突破性治疗品种。药捷安康-B提示，根据上市规则第18A.08条，公司无法保证最终能够成功开发及销售相关产品。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657633778","title":"Genecare Development Limited减持药捷安康-B(02617)46.75万股 每股作价约12.58港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2657633778","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657633778?lang=zh_cn&edition=full","pubTime":"2026-08-06 19:20","pubTimestamp":1786015233,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，8月5日，Genecare Development Limited减持药捷安康-B(02617)46.75万股，每股作价12.5786港元，总金额约为588.05万港元。减持后最新持股数目约为2149.29万股，最新持股比例为6.87%。本交易涉及其他关联方：陈谭庆芬、Ghalibo (PTC) Limited、Morningside Holdings (Asia) Limited、Morningside Bio-Ventures Limited、Morningside Venture (I) Investments Limited。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1476921.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02617","BK1161","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121120334","title":"药捷安康-B：Morningside Holdings (Asia) Limited减持，好仓比例降至6.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=1121120334","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121120334?lang=zh_cn&edition=full","pubTime":"2026-08-06 17:15","pubTimestamp":1786007754,"startTime":"0","endTime":"0","summary":"Morningside Holdings (Asia) Limited于2026年8月5日以每股均价12.5786港元卖出药捷安康-B（02617）股份46.75万股，涉资约588.05万港元。Morningside Holdings (Asia) Limited此次减持前持有药捷安康-B好仓2196.04万股，占比7.02%；减持后持股量为2149.29万股，好仓比例降至6.87%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175707164","title":"药捷安康-B：Morningside Venture (I) Investments Limited减持，好仓比例降至6.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=1175707164","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1175707164?lang=zh_cn&edition=full","pubTime":"2026-08-06 17:14","pubTimestamp":1786007680,"startTime":"0","endTime":"0","summary":"Morningside Venture (I) Investments Limited于2026年8月5日以每股均价12.5786港元卖出药捷安康-B股份46.75万股，涉资约588.05万港元。Morningside Venture (I) Investments Limited此次减持前持有药捷安康-B好仓2196.04万股，占比7.02%；减持后持股量为2149.29万股，好仓比例降至6.87%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126733332","title":"药捷安康-B：Morningside Bio-Ventures Limited减持，好仓比例降至6.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=1126733332","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1126733332?lang=zh_cn&edition=full","pubTime":"2026-08-06 17:12","pubTimestamp":1786007572,"startTime":"0","endTime":"0","summary":"Morningside Bio-Ventures Limited于2026年8月5日以每股均价12.5786港元卖出药捷安康-B（02617）股份46.75万股，涉资约588.05万港元。Morningside Bio-Ventures Limited此次减持前持有药捷安康-B好仓2196.04万股，占比7.02%；减持后持股量为2149.29万股，好仓比例降至6.87%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102010843","title":"药捷安康-B：Ghalibo (PTC) Limited减持，好仓比例降至6.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=1102010843","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1102010843?lang=zh_cn&edition=full","pubTime":"2026-08-06 17:12","pubTimestamp":1786007559,"startTime":"0","endTime":"0","summary":"Ghalibo (PTC) Limited于2026年8月5日以每股均价12.5786港元卖出46.75万股药捷安康-B股份，涉资约588.05万港元。Ghalibo (PTC) Limited此次减持前持有药捷安康-B好仓2196.04万股，占比7.02%；减持后持股量为2149.29万股，好仓比例降至6.87%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180080056","title":"药捷安康-B：陈谭庆芬减持，好仓比例降至6.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=1180080056","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180080056?lang=zh_cn&edition=full","pubTime":"2026-08-06 17:12","pubTimestamp":1786007557,"startTime":"0","endTime":"0","summary":"陈谭庆芬于2026年8月5日以每股均价12.5786港元卖出药捷安康-B（02617）股份46.75万股，涉资约588.05万港元。陈谭庆芬此次减持前持有药捷安康-B好仓2196.04万股，占比7.02%；减持后持股量为2149.29万股，好仓比例降至6.87%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139351553","title":"药捷安康-B：Genecare Development Limited减持，好仓比例降至6.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=1139351553","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1139351553?lang=zh_cn&edition=full","pubTime":"2026-08-06 17:11","pubTimestamp":1786007507,"startTime":"0","endTime":"0","summary":"Genecare Development Limited于2026年8月5日以每股均价12.5786港元卖出药捷安康-B股份46.75万股，涉资约588.05万港元。Genecare Development Limited此次减持前持有药捷安康-B好仓2196.04万股，占比7.02%；减持后持股量为2149.29万股，好仓比例降至6.87%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122953396","title":"异动解读｜药捷安康-B盘中上涨5.08%，密集回购叠加多管线临床进展推动股价延续反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1122953396","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1122953396?lang=zh_cn&edition=full","pubTime":"2026-08-06 09:43","pubTimestamp":1785980635,"startTime":"0","endTime":"0","summary":"8月6日，药捷安康-B盘中上涨5.08%，报12.26港元，成交额4650.54万港元，延续近日强势反弹态势。消息面上，公司自7月以来密集回购H股，7月内累计回购71.8万股，合计耗资逾700万港元，释放管理层对公司价值的信心。同时，公司于7月24日向67名员工授出约525.89万股H股激励，进一步绑定核心团队利益。管线方面，公司核心产品替恩戈替尼全球注册性III期临床试验已完成入组，TT-00973及TT-01488两款产品II期临床亦先后获批开展，多管线推进提升市场预期。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"药捷安康-B盘中上涨5.08%，密集回购叠加多管线临床进展推动股价延续反弹","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169653122","title":"异动解读｜药捷安康-B盘中上涨8.83%，港股创新药板块持续走强叠加公司密集回购","url":"https://stock-news.laohu8.com/highlight/detail?id=1169653122","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169653122?lang=zh_cn&edition=full","pubTime":"2026-08-05 09:52","pubTimestamp":1785894767,"startTime":"0","endTime":"0","summary":"8月5日，药捷安康-B盘中上涨8.83%，报12.7港元，成交额8113.72万港元，延续前一交易日强势反弹态势。消息面上，港股创新药板块近日集体走强，内资持续加仓创新药标的，外资亦有布局。公司层面，药捷安康自7月以来密集回购H股，7月内累计回购71.8万股，合计耗资逾700万港元，释放管理层对公司价值的信心。此外，公司于7月24日向67名员工授出约525.89万股H股激励，进一步绑定核心团队利益。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"药捷安康-B盘中上涨8.83%，港股创新药板块持续走强叠加公司密集回购","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172432304","title":"药捷安康-B更新7月股份变动月报表，股本保持407,918,633股","url":"https://stock-news.laohu8.com/highlight/detail?id=1172432304","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172432304?lang=zh_cn&edition=full","pubTime":"2026-08-04 18:46","pubTimestamp":1785840390,"startTime":"0","endTime":"0","summary":"药捷安康 (南京) 科技股份有限公司于2026年8月4日披露截至2026年7月31日的证券变动月报表。公告显示，公司法定注册股本总额维持人民币407,918,633元不变，其中H股注册资本为312,687,673股，非上市普通股注册资本为95,230,960股。股权激励方面，公司于2026年7月24日根据2026年H股奖励计划授出合计5,258,900股H股奖励份额，其中包含2,442,000份购股权和2,816,900股股份奖励。购回股份方面，公司于7月内多次回购H股股票，涉及数量合计718,000股，并将其持为库存股份。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106062057","title":"异动解读｜药捷安康-B盘中上涨18%，港股创新药板块集体走强","url":"https://stock-news.laohu8.com/highlight/detail?id=1106062057","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1106062057?lang=zh_cn&edition=full","pubTime":"2026-08-04 15:53","pubTimestamp":1785830005,"startTime":"0","endTime":"0","summary":"8月4日，药捷安康-B盘中上涨18%，报11.8港元，成交额4.1亿港元，较此前低位明显放量反弹。消息面上，港股通创新药板块当日集体走强，银诺医药涨超11%，百奥赛图涨超5%，和黄医药、荣昌生物涨超4%。此外，近一个月内资重点加仓药捷安康等创新药企，外资亦有布局。同时公司自7月以来持续回购H股，累计耗资逾700万港元，释放管理层信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"药捷安康-B盘中上涨18%，港股创新药板块集体走强","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126265990","title":"药捷安康-B（02617）授出逾525.89万股H股激励股份及购股权","url":"https://stock-news.laohu8.com/highlight/detail?id=1126265990","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1126265990?lang=zh_cn&edition=full","pubTime":"2026-07-24 21:01","pubTimestamp":1784898078,"startTime":"0","endTime":"0","summary":"2026年7月24日，药捷安康（南京）科技股份有限公司公告，根据已获股东批准的H股奖励计划，公司向67名员工参与者授出合计5,258,900股H股对应的激励，包括2,816,900份股份奖励及2,442,000份购股权。董事长兼首席执行官吴永谦博士获授购股权300,000份；– 购股权：分别在首、次、三周年日按30%/30%/40%比例归属。董事会确认，本次授予不会导致董事个人激励授予超出上市规则规定的0.1%限额，亦无需股东另行批准。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653087375","title":"药捷安康-B(02617)授出合共525.89万股H股奖励股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2653087375","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653087375?lang=zh_cn&edition=full","pubTime":"2026-07-24 21:00","pubTimestamp":1784898000,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药捷安康-B(02617)公布，于2026年7 月24日，公司根据H股奖励计划的条款，向67名雇员参与者授出合共281.69万份股份奖励及244.2万份购股权，涉及合共525.89万股H股奖励股份。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1472169.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.transtherabio.com","stockEarnings":[{"period":"1week","weight":-0.0754},{"period":"1month","weight":0.0325},{"period":"3month","weight":-0.783},{"period":"6month","weight":-0.8456},{"period":"1year","weight":-0.7493},{"period":"ytd","weight":-0.9061}],"compareEarnings":[{"period":"1week","weight":-0.0077},{"period":"1month","weight":0.0611},{"period":"3month","weight":-0.0279},{"period":"6month","weight":-0.051},{"period":"1year","weight":0.03},{"period":"ytd","weight":0.0009}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"药捷安康（南京）科技股份有限公司是一家从事生物制药的中国公司，主要专注于发现及开发肿瘤、炎症及心脏代谢疾病小分子创新疗法。该公司的核心产品Tinengotinib是一种处于注册临床阶段的内部发现和开发的MTK抑制剂，适用于某些复发或难治的耐药实体瘤。该公司的肿瘤产品线包括TT-00973（针对 AXL）、TT-01488（用于血液系统恶性肿瘤）、TT-01688（用于炎症性疾病）和 TT-00920（用于慢性心力衰竭）。这些产品能够对多种癌症类型（包括前列腺癌、肝癌、乳腺癌和BTC）产生疗效。它还可用于治疗肝细胞癌、乳腺癌、胆道癌和Pan-FGFR实体瘤。","exchange":"SEHK","name":"药捷安康-B","nameEN":"TRANSTHERA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"药捷安康-B(02617)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供药捷安康-B(02617)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"药捷安康-B,02617,药捷安康-B股票,药捷安康-B股票老虎,药捷安康-B股票老虎国际,药捷安康-B行情,药捷安康-B股票行情,药捷安康-B股价,药捷安康-B股市,药捷安康-B股票价格,药捷安康-B股票交易,药捷安康-B股票购买,药捷安康-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"药捷安康-B(02617)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供药捷安康-B(02617)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}